Late cardiopulmonary toxicity after treatment for Hodgkin's disease.

por Allavena, C., Conroy, T., Aletti, P., Bey, P., Lederlin, P.
Publicado 1992

P18-01. Exquisite specificity of CTL response to the M184V mutation

por Pacheco, Y, Allavena, C, Guilloux, Y, Ferre, V, Raffi, F, McIlroy, D
Publicado 2009

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort

por Cuzin, L, Allavena, C, Levy-Bachelot, L, Valantin, MA, Mellliez, H, Pugliese, P, Poizot-Martin, I, Duvivier, C, Finkielsztejn, L, Abel, S
Publicado 2010

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort

por Cuzin, L., Cotte, L., Delpierre, C., Allavena, C., Valantin, M-A., Rey, D., Delobel, P., Pugliese, P., Raffi, F., Cabié, A.
Publicado 2019

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015

por Poizot‐Martin, I., Obry‐Roguet, V., Duvivier, C., Lions, C., Huleux, T., Jacomet, C., Ferry, T., Cheret, A., Allavena, C., Bani‐Sadr, F., Palich, R., Cabié, A., Fresard, A., Pugliese, P., Delobel, P., Lamaury, I., Hustache‐Mathieu, L., Brégigeon, S., Makinson, A., Rey, D.
Publicado 2020